Giant cell arteritis (GCA) is an inflammation of the arteries which causes multiple symptoms including head pain and tenderness and can result in vision loss. touchIMMUNOLOGY caught up with Dr. Lisa Christ (University of Bern, Inselspital, Bern, Switzerland) to discuss the epidemiology and prognosis of GCA, the limitations of glucocorticoid treatment and the rationale for targeting interleukin-6 in GCA.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial.’ (Abstract number: 0470) was presented at the ACR Convergence, November 10–14, 2022.
- Could you tell us a little about giant cell arteritis (GCA), its epidemiology and prognosis? (0:16)
- What are the limitations of glucocorticoid treatment for GCA? (1:04)
- What is the rationale for targeting interleukin-6 in the treatment of GCA? (1:38)
Disclosures: Lisa Christ discloses receiving grant/ research support from F. Hoffmann-La Roche, Gilead Sciences, and Pfizer; serving on advisory boards for Bristol-Myers Squibb and Novartis; and other financial support from F. Hoffmann-La Roche, Bristol-Myers Squibb, and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Atiya Henry.
Filmed in coverage of the ACR Convergence 2022.
Share this Video
Related Videos In Vasculitis
Molecular phenotyping of giant cell arteritis patients based on the serum protein signature: Lisa Christ, EULAR 2023
There is a lack of biomarkers to profile phenotypes in giant cell arteritis (GCA) and predict potential complications. Serum protein profiling may identify molecular-based phenotypes and facilitate personalized medicine approaches. touchIMMUNOLOGY were delighted to speak with Dr Lisa Christ (Universitätsspital Bern Bern, Switzerland) about her study which investigated the serum protein signature of clinically defined GCA […]
Molecular Phenotyping of Giant Cell Arteritis: Lisa Christ, EULAR 2023
Giant cell arteritis (GCA) is a primary systemic vasculitis characterised by systemic inflammation and vascular insufficiency of large and medium blood vessels which may lead to end-organ damage in patients age 50 and older. touchIMMUNOLOGY were delighted to speak with Dr Lisa Christ (Universitätsspital Bern Bern, Switzerland) about the unmet needs in the pathogenesis of […]
Naomi J Patel, ACR 2022: Impact of tocilizumab on HbA1C during giant cell arteritis treatment
GiACTA was a randomized, double-blind, placebo-controlled study that investigated the safety and efficacy of tocilizumab, an IL-6 receptor antagonist, in patients with giant cell arteritis. touchIMMUNOLOGY were delighted to speak with Dr. Naomi J Patel (Massachusetts General Hospital, Boston, MA, USA) to discuss the aims, design and findings from her post-hoc analysis of the GiACTA […]